Published August 2015 | Version v1
Journal article

Mucosal vaccination by adenoviruses displaying reovirus sigma 1

  • 1. Department of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902 (United States)
  • 2. Department of Cell Biology, Department of Natural Sciences, Western New Mexico University, Silver City, NM 88062 (United States)
  • 3. Nephrology Training Program, Mayo Clinic, Rochester, MN 55902 (United States)
  • 4. Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902 (United States)
  • 5. Department of Physics, University of Houston, Houston, TX 77004 (United States)
  • 6. Department of Immunology and Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55902 (United States)

Description

We developed adenovirus serotype 5 (Ad5) vectors displaying the sigma 1 protein from reovirus as mucosal vaccines. Ad5-sigma retargets to JAM-1 and sialic acid, but has 40-fold reduced gene delivery when compared to Ad5. While weaker at transduction, Ad5-sigma generates stronger T cell responses than Ad5 when used for mucosal immunization. In this work, new Ad5-fiber-sigma vectors were generated by varying the number of fiber β-spiral shaft repeats (R) between the fiber tail and sigma. Increasing chimera length led to decreasing insertion of these proteinsAd5 virions. Ad-R3 and R14 vectors effectively targeted JAM-1 in vitro while R20 did not. When wereused to immunize mice by the intranasal route, Ad5-R3-sigma produced higher serum and vaginal antibody responses than Ad5. These data suggest optimized Ad-sigma vectors may be useful vectors for mucosal vaccination. - Highlights: • Constructed adenoviruses (Ads) displaying different reovirus sigma 1 fusion proteins. • Progressively longer chimeras were more poorly encapsidated onto Ad virions. • Ad5-R3-sigma mediated better systemic and mucosal immune responses than Ad5

Availability note (English)

Available from http://dx.doi.org/10.1016/j.virol.2015.02.050

Additional details

Identifiers

DOI
10.1016/j.virol.2015.02.050;
PII
S0042-6822(15)00115-4;

Publishing Information

Journal Title
Virology
Journal Volume
482
Journal Page Range
p. 60-66
ISSN
0042-6822
CODEN
VIRLAX

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47039962
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
ADENOVIRUS; ANTIBODIES; CHIMERAS; COMPARATIVE EVALUATIONS; DELIVERY; FIBERS; GENES; IN VITRO; LENGTH; MICE; PROTEINS; SIALIC ACID; VACCINES
Descriptors DEC
ANIMALS; DIMENSIONS; EVALUATION; MAMMALS; MICROORGANISMS; MOSAICISM; ONCOGENIC VIRUSES; ORGANIC COMPOUNDS; PARASITES; RODENTS; VERTEBRATES; VIRUSES

Optional Information

Copyright
Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.